Cancer and multiple sclerosis in the era of disease-modifying treatments

Journal of Neurology

Volumn 258, Issue 7, 2011, Pages 1304-1311

  Lebrun, Christine ^a   Vermersch, Patrick ^b   Brassat, David ^c   Defer, Gilles ^d   Rumbach, Lucien ^e   Clavelou, Pierre ^f   Debouverie, Marc ^g   De Seze, Jérôme ^h   Wiertlevsky, Sandrine ⁱ   Heinzlef, Olivier ^j   Tourbah, Ayman ^k   Fromont, Agnes ^l   Frenay, Marc ^m  

^a PASTEUR HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c CHU PURPAN   (France)

^d CHU CÔTE DE NACRE   (France)

^e UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^f SERVICE DE RHUMATOLOGIE   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

^h UNIVERSITY HOSPITAL OF STRASBOURG   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j CENTRE HOSPITALIER INTERCOMMUNAL   (France)

^k REIMS UNIVERSITY HOSPITAL   (France)

^l DIJON UNIVERSITY HOSPITAL   (France)

^m Pharmacologie Clinique   (France)

more..

Author keywords

Cancer; Immunosuppressive drug therapies; Interferon beta; Multiple sclerosis

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; FINGOLIMOD; GLATIRAMER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; TERIFLUNOMIDE;

ACUTE LEUKEMIA; ADULT; ARTICLE; AUTOIMMUNE DISEASE; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RISK; CENTRAL NERVOUS SYSTEM TUMOR; DIGESTIVE SYSTEM CANCER; DISEASE COURSE; FEMALE; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIPLE SCLEROSIS; NEOPLASM; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SKIN CANCER; TREATMENT DURATION; UTERINE CERVIX CANCER;

ADULT; DATABASES, FACTUAL; FEMALE; FRANCE; HUMANS; IMMUNOLOGIC FACTORS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEOPLASMS; RISK FACTORS; YOUNG ADULT;

EID: 79961027736     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-5929-9     Document Type: Article

References (37)

1. H Moller RW Kneller JD Boice JH Olsen 1991 Cancer incidence following hospitalization for multiple sclerosis in Denmark Acta Neurol Scand 84 214 220 1950464 10.1111/j.1600-0404.1991.tb04941.x 1:STN:280:DyaK38%2FlslGqtA%3D%3D
2. NM Nielsen K Rostgaard S Rasmussen, et al. 2006 Cancer risk among patients with multiple sclerosis: a population-based register study Int J Cancer 118 979 984 16152598 10.1002/ijc.21437 1:CAS:528:DC%2BD28Xhtlais7c%3D (Pubitemid 43157674)
3. J Palo J Duchesne J Wilkstrom 1977 Malignant diseases among patients with multiple sclerosis J Neurol 216 217 222 72140 10.1007/BF00313623 1:STN:280:DyaE1c%2FivVWquw%3D%3D (Pubitemid 8183821)
4. R Midgard E Glattre M Gronning, et al. 1996 Multiple sclerosis and cancer in Norway. A retrospective cohort study Acta Neurol Scand 93 411 415 8836302 10.1111/j.1600-0404.1996.tb00019.x 1:STN:280:DyaK28vjtleitw%3D%3D (Pubitemid 26232751)
5. ML Sumelahti E Pukkala M Hakama 2004 Cancer incidence in MS: a 35-year follow-up Neuroepidemiology 23 5 224 227 15316248 10.1159/000079947 (Pubitemid 39179151)
6. C Lebrun M Debouverie P Vermersch P Clavelou L Rumbach J de Seze S Wiertlevski, et al. 2008 Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis Mult Scler 14 399 415 18420778 10.1177/1352458507083625 (On behalf le Club Francophone de la Sclérose en Plaques (CFSEP)) (Pubitemid 351676435)
7. C Confavreux 1994 Establishement and use of multiple sclerosis registers. EDMUS Ann Neurol 36 136 139 10.1002/ana.410360733 (Pubitemid 24220862)
8. WI Mc Donald A Compston G Edan D Goodkin HP Hartung FD Lublin HF Mc Farland, et al. 2001 Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis Ann Neurol 50 121 127 10.1002/ana.1032 1:STN:280:DC%2BD38%2FitFOhug%3D%3D (Pubitemid 32591472)
9. D Taeger Y Sun U Keil K Straif 2000 A stand-alone windows application for computing exact person-years, standardized mortality ratios and confidence intervals in epidemiological studies Epidemiology 11 607 608 10955416 10.1097/00001648-200009000-00019 1:STN:280:DC%2BD3M%2FntlSnuw%3D%3D (Pubitemid 30660042)
10. Leray E, Leray E, Morrissey SP et al (2007) Long-term survival of patients with multiple sclerosis in West France. Mult Scler 13(7):865-874 (Pubitemid 351540857)
11. S Bahmanyar SM Montgomery J Hillert A Ekbom T Olsson 2009 Cancer risk among patients with multiple sclerosis and their parents Neurology 72 1170 1177 19332695 10.1212/01.wnl.0000345366.10455.62 1:STN:280:DC%2BD1M3ksFSjtg%3D%3D
12. A Weill N Vallier B Salanave R Bourrel M Cayla C Suarez P Ricordeau, et al. 2006 Fréquence des trente affections de longue durée pour les bénéficiaires du régime général de l'assurance maladie en 2004 Prat et Org des soins 37 3 173 188
13. E Kingwell H Tremlett 2009 Interferons and multiple sclerosis: is it plausible that beta-IFN treatment could influence the risk of cancer among MS patients? Expert Rev Neurother 9 9 1263 1265 19769440 10.1586/ern.09.76
14. A Achiron Y Barak M Gail 2005 Cancer incidence in multiple sclerosis patients and effects of immunomodulatory treatments Breast Cancer Res Treat 89 265 270 15754125 10.1007/s10549-004-2229-4 1:CAS:528:DC%2BD2MXitVKlsbg%3D (Pubitemid 43293074)
15. Sandberg-Wollheim M, Kornmann G, Stam Moraga M, Alteri E (2010) Risk of malignancy in patients with multiple sclerosis receiving subcutaneous interferon beta 1a. 62nd annual meeting of the American Academy of Neurology 2010. Neurology P01.167
16. OR Hommes HL Weiner 2002 Results of an international questionnaire on immunosuppressive treatment of MS Mult Scler 8 139 141 11990871 10.1191/1352458502ms791oa 1:STN:280:DC%2BD383ltFKhug%3D%3D (Pubitemid 34256751)
17. MP Amato G Pracucci G Ponziani G Siracusa L Fratiglioni L Amaducci 1993 Long term safety of azathioprine therapy in MS Neurology 43 831 833 8469348 1:STN:280:DyaK3s3is1WhtA%3D%3D (Pubitemid 23121984)
18. L Taylor RA Hugues K Mc Pherson 2004 The risk of cancer from azathioprine as a treatment for multiple sclerosis Eur J Neurol 11 141 14748776 10.1046/j.1351-5101.2003.00721.x 1:STN:280:DC%2BD2c%2FkvVCnsQ%3D%3D (Pubitemid 38230791)
19. PL Yudkin GW Ellison A Ghezzi, et al. 1991 Overview of azathioprine treatment in multiple sclerosis Lancet 338 1051 1055 1681364 10.1016/0140-6736(91)91909-E 1:STN:280:DyaK38%2Fhs12luw%3D%3D
20. C Confavreux P Saddier J Grimaud T Moreau P Adeleine G Aimard 1996 Risk of cancer from azathioprine therapy in MS Neurology 46 1607 1612 8649558 1:STN:280:DyaK283kvV2ktQ%3D%3D
21. N Koch-Henriksen 1999 The Danish Multiple Sclerosis Registry: a 50-year follow-up Mult Scler 5 293 296 10467392 1:STN:280:DyaK1MzpvVylsg%3D%3D (Pubitemid 29405629)
22. DE Goodkin MM Daughtry S Vanderburg-Medenddorp 1992 Incidence of malignancy following cyclophosphamide or azathioprine treatment for MS Ann Neurol 32 257
23. G Edan B Brochet M Clanet P Clavelou C Confavreux M Debouverie O Heinzlef C Lebrun, et al. 2004 Safety profile of mitoxantrone in a cohort of 802 MS patients Neurology 62 7 P06 P093
24. CH Polman PW O'Connor E Havrdova, et al. 2006 A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 899 910 16510744 10.1056/NEJMoa044397 1:CAS:528:DC%2BD28XitVertL4%3D
25. OA Khan SC Bauserman MI Rothman EF Aldrich HS Panitch 1997 Concurrence of multiple sclerosis and brain tumor: clinical correlation Neurology 48 1330 1333 9153467 1:STN:280:DyaK2s3pslygtw%3D%3D (Pubitemid 27240558)
26. S Hofer M Linnebank M Weller S Bahmanyar SM Montgomery J Hillert A Ekbom T Olsson 2010 Cancer risk among patients with multiple sclerosis and their parents Neurology 74 7 614 615 20157167 10.1212/WNL.0b013e3181c777b7
27. P Vineis P Crosignani C Vignano, et al. 2001 Lymphomas and multiple sclerosis in multicenter case-control study Epidemiology 12 134 135 11138810 10.1097/00001648-200101000-00023 1:STN:280:DC%2BD3M7hsFGqsg%3D%3D (Pubitemid 32006474)
28. RM Ransohoff 2009 Natalizumab, multiple sclerosis, and primary central nervous system lymphoma: enigma, wrapped in mystery, enclosed in conundrum Ann Neurol 66 3 259 261 19798722 10.1002/ana.21850
29. MJ Goldacre V Seagroatt D Yeates, et al. 2004 Skin cancer In people with multiple sclerosis: a record linkage study J Epidemiol Community Health 58 142 144 14729897 10.1136/jech.58.2.142 1:STN:280:DC%2BD2c%2FivFymtw%3D%3D (Pubitemid 38130483)
30. R Bergamaschi C Montomoli 2009 Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence? Mult Scler 15 12 1532 1533 20019096 10.1177/1352458509347154 1:CAS:528:DC%2BC3cXhtlaqsrg%3D
31. MA Panzara C Bozic AW Sandrock 2008 More on melanoma with transdifferentiation N Engl J Med 359 99 18596284 10.1056/NEJMc086089 1:CAS:528:DC%2BD1cXotFChtbg%3D
32. Castela E, Lebrun C, Laffon-Pioger M, Rocher F, Cohen M, Bahadoran P, Ortonne P, Lacour JP, Passeron T (2010) Natalizumab and risk of melanoma: a prospective follow up of patients treated by natalizumab for multiple sclerosis. Arch Dermatol Sept 20:E1-E5
33. AA Pace JP Zajicek 2009 Melanoma following treatment with alemtuzumab for multiple sclerosis Eur J Neurol 16 e70 e71 19222552 10.1111/j.1468-1331.2009. 02552.x 1:STN:280:DC%2BD1M3mtVKhsQ%3D%3D
34. JA Cohen F Barkhof G Comi HP Hartung BO Khatri X Montalban J Pelletier, et al. 2010 Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 5 402 415 20089954 10.1056/NEJMoa0907839 1:CAS:528:DC%2BC3cXhvVWrsbk%3D
35. L Kappos LW Radue P O'Connor C Polman R Hohlfeld P Calabresi K Selmaj, et al. 2010 A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 1 15 10.1056/NEJMoa0909494
36. G Giovannoni G Comi S Cook K Rammohan P Rieckmann PS Sorensen P Vermersch, et al. 2010 A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis N Engl J Med 362 5 416 426 20089960 10.1056/NEJMoa0902533 1:CAS:528:DC%2BC3cXhvVaitr0%3D
37. T Herzinger B Kleuser M Schafer-Korting HC Korting 2007 Sphingosine-1-phosphate signaling and the skin Am J Clin Dermatol 8 6 329 336 18039015 10.2165/00128071-200708060-00002 (Pubitemid 350174535)